Search for evidence-based approaches for the prevention and palliation of hand-foot skin reaction(HFSR) caused by the multikinase inhibitors(MKIs)

Oncologist

Volumn 14, Issue 3, 2009, Pages 291-302

  Anderson, Roger ^a   Jatoi, Aminah ^b   Robert, Caroline ^c   Wood, Laura S ^d   Keating, Karen N ^e   Lacouture, Mario E ^f  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

^b MAYO CLINIC CANCER CENTER   (United States)

^c INSTITUT GUSTAVE ROUSSY   (France)

^d TAUSSIG CANCER INSTITUTE   (United States)

^e BAYER CORPORATION   (United States)

^f NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; AVEENO; BAG BALM; BLUE LIZARD; CAPECITABINE; CETAPHIL; CYCLOOXYGENASE 2 INHIBITOR; CYTARABINE; DOXORUBICIN; EMITEFUR; EMOLLIENT AGENT; FLOXURIDINE; FLUOROURACIL; GLUCOCORTICOID; GOLD BOND; IRINOTECAN; KERALAC; KERASAL; KERATOLYTIC AGENT; LANOLIN ALCOHOL; NAVELBINE; NEUTROGENA; PHOSPHOTRANSFERASE INHIBITOR; PYRIDOXINE; SALICYLIC ACID; SORAFENIB; TAZAROTENE; TEGAFUR; TOPICAL AGENT; UDDERLY SMOOTH; UNCLASSIFIED DRUG; UREA; XIPAMIDE;

ARTICLE; DATA BASE; EVIDENCE BASED PRACTICE; HAND FOOT SYNDROME; HUMAN; HYPERKERATOSIS; OINTMENT; OUTCOME ASSESSMENT; PAIN; PALLIATIVE THERAPY; PATHOGENESIS; PATIENT EDUCATION; PRIORITY JOURNAL; PROPHYLAXIS; QUALITY OF LIFE; SKIN CARE; SKIN MANIFESTATION; SKIN TOXICITY; TREATMENT DURATION;

DRUG ERUPTIONS; FOOT DERMATOSES; HAND DERMATOSES; HUMANS; PALLIATIVE CARE; PROTEIN KINASE INHIBITORS;

EID: 64049100782     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2008-0237     Document Type: Article

References (51)

1. Cancer.net. Skin Reactions to Targeted Therapies. Alexandria, VA: American Society of Clinical Oncology, 2007. Available at http://www.cancer. net/patient/Diagnosis + and +Treatment/Treating + Cancer/Managing + Side + Effects/Skin + Reactions + to + Targeted + Therapies, accessed August 31, 2008.
2. Chu D, Lacouture ME, Fillos T et al. Risk of hand-foot skin reaction with sorafenib: A systematic review and meta-analysis. Acta Oncol 2008;47: 176-186.
3. Janusch M, Fischer M, Marsch WC et al. The hand-foot syndrome-a frequent secondary manifestation in antineoplastic chemotherapy. Eur J Dermatol 2006;16:494-499.
4. Wood LS, Manchen B. Sorafenib: A promising new targeted therapy for renal cell carcinoma. Clin J Oncol Nurs 2007;11:649-656.
5. Lacouture ME, Wu S, Robert C et al. Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib. The Oncologist 2008;13:1001-1011.
6. Autier J, Mateus C, Wechsler J et al. [Cutaneous side effects of sorafenib and sunitinib.] Ann Dermatol Venereol 2008;135:148-153. In French.
7. Heidary N, Naik H, Burgin S. Chemotherapeutic agents and the skin: An update. J Am Acad Dermatol 2008;58:545-570.
8. Porta C, Paglino C, Imarisio I et al. Uncovering Pandora's vase: The growing problem of new toxicities from novel anticancer agents. The case of sorafenib and sunitinib. Clin Exp Med 2007;7:127-134.
9. Deslandres M, Sibaud V, Chevreau C et al. [Cutaneous side effects associated with epidermal growth factor receptor and tyrosine kinase inhibitors.] Ann Dermatol Venereol 2008;Spec No 1:16-24. In French.
10. Pföhler C, Ugurel S. [Cutaneous reactions to molecular targeted therapies.] Hautarzt 2008;59:814-820. In German.
11. Robert C, Soria JC, Spatz A et al. Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol 2005;6:491-500.
12. Yang CH, Lin WC, Chuang CK et al. Hand-foot skin reaction in patients treated with sorafenib: A clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy. Br J Dermatol 2008; 158:592-596.
13. National Cancer Institute. CTC v2.0 and Common Terminology Criteria for Adverse Events v3.0(CTCAE). Bethesda, MD: National Cancer Institute, 2006. Available at http://ctep.info.nih.gov/reporting/ctc.html, accessed August 31, 2008.
14. Nexavar [package insert]. West Haven, CT: Bayer Healthcare Pharmaceuticals, 2007.
15. Bhojani N, Jeldres C, Patard JJ et al. Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma. Eur Urol 2008;53:917-930.
16. Lacouture ME, Basti S, Patel J et al. The SERIES clinic: An interdisciplinary approach to the management of toxicities of EGFR inhibitors. J Support Oncol 2006;4:236-238.
17. Wood L. Managing the side effects of sorafenib and sunitinib. Community Oncol 2006;3:558-562.
18. Webster-Gandy JD, How C, Harrold K. Palmar-plantar erythrodysesthesia(PPE): A literature review with commentary on experience in a cancer centre. Eur J Oncol Nurs 2007;11:238-246.
19. Robert C. [Cutaneous side effects of antiangiogenic agents.] Bull Cancer 2007;94 Spec No:S260-S264. In French.
20. Staehler M, Haseke N, Schoppler G et al. [Managing the side effects ofan-giogenetic inhibitors in metastatic renal cell carcinoma.] Urologe A 2006; 45:1333-1342. In German.
21. Gressett SM, Stanford BL, Hardwicke F. Management of hand-food syndrome induced by capecitabine. J Oncol Pharm Pract 2006;12:131-141.
22. Lee S, Lee S, Chun Y et al. Pyridoxine is noteffective for the prevention of hand foot syndrome(HFS) associated with capecitabine therapy: Results of a randomized double-blind placebo-controlled study. J Clin Oncol 2007; 25:9007.
23. Mortimer JE, Lauman M, Tan B et al. Pyridoxine treatment and prevention of hand-and-foot syndrome in patients receiving capecitabine. J Oncol Pharm Pract 2003;9:161-166.
24. Skin reactions and cancer therapy-Guidelines for identifying and managing skin-related side effects during your therapy. West Haven, CT; Emeryville, CA: Bayer Healthcare Pharmaceuticals, Onyx Pharmaceuticals, 2008:1-13.
25. Eskens FA, Verweij J. The clinical toxicity profile of vascular endothelial growth factor(VEGF) and vascular endothelial growth factor receptor(VEGFR) targeting angiogenesis inhibitors: A review. Eur J Cancer 2006; 42:3127-3139.
26. Lacouture ME, Reilly LM, Gerami P et al. Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib. Ann Oncol 2008;19:1955-1961.
27. Scheithauer W, Blum J. Coming to grips with hand-foot syndrome. Insights from clinical trials evaluating capecitabine. Oncology(Williston Park) 2004;18:1161-1168, 1173; discussion 1173-1176, 1181-1184.
28. Sutent [package insert]. New York, NY: Pfizer Labs, 2007.
29. van der Veldt AA, van den Eertwegh AJ, Boven E. [Adverse effects of the tyrosine-kinase inhibitor sunitinib, a new drug for the treatment of ad- vancedrenal-cellcancer.] NedTijdschrGeneeskd2007;151:1142-1147. In Dutch.
30. Escudier B, Eisen T, Stadler WM et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356:125-134.
31. Autier J, Escudier B, Wechsler J et al. Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor. Arch Dermatol 2008;144:886-892.
32. Bennani-Lahlou M, Mateus C, Escudier B et al. [Eruptive nevi associated with sorafenib treatment.] Ann Dermatol Venereol 2008;135:672-674. In French.
33. Kong HH, Sibaud V, Chanco Turner ML et al. Sorafenib-induced eruptive melanocytic lesions. ArchDermatol 2008;144:820-822.
34. Bajetta E, Procopio G, Verzoni E et al. Renal cell cancer and sorafenib: Skin toxicity and treatmentoutcome. Tumori 2007;93:201-203.
35. Grünwald V, Heinzer H, Fiedler W. Managing side effects of angiogenesis inhibitors in renal cell carcinoma. Onkologie 2007;30:519-524.
36. Esper P, Gale D, Muehlbauer P. What kind of rash is it? Deciphering the dermatologic toxicities of biologic and targeted therapies. Clin J Oncol Nurs 2007;11:659-666.
37. Ahmad T, Eisen T. Kinase inhibition with BAY 43-9006 in renal cell carcinoma. ClinCancer Res 2004;10(suppl):6388S-6392S.
38. Lacouture ME, Boerner SA, Lorusso PM. Non-rash skin toxicities associated withnoveltargetedtherapies. ClinLung Cancer2006;8(suppl1):S36-S42.
39. Abou-Alfa GK, Schwartz L, Ricci S et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006;24: 4293-4300.
40. Llovet JM, Ricci S, Mazzaferro V et al. Sorafenib in advanced hepatocel- lular carcinoma. N Engl J Med 2008;359:378-390.
41. Patiyil S, Chan SN, Jatoi A. New agents, new rashes: An update on skin complications from cancer chemotherapy. Curr Oncol Rep 2006;8:269- 274.
42. Anderson R, Rajagopalan R. Responsiveness of the Dermatology-specific Quality of Life(DSQL) instrument to treatment for acne vulgaris in a placebo-controlled clinical trial. Qual Life Res 1998;7:723-734.
43. ChrenMM, LasekRJ, SahayAPet al. MeasurementpropertiesofSkindex-16: A brief quality-of-life measure for patients with skin diseases. J Cutan Med Surg 2001;5:105-110.
44. Pérez-Soler R, Delord JP, Halpern A et al. HER1/EGFR inhibitor-associated rash: Future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum. The Oncologist 2005;10:345-356.
45. Robert C, Escudier B. Cutaneous side effects ofmultikinase inhibitors used in renal cell cancer. Oncology News International 2007;May:1-20.
46. Vukelja SJ, Lombardo FA, James WD et al. Pyridoxine for the palmar-plantarerythrodysesthesiasyndrome. AnnInternMed 1989;111:688-689.
47. Lin E, Morris JS, Ayers GD. Effect of celecoxib on capecitabine-induced hand-foot syndrome and antitumor activity. Oncology(Williston Park) 2002;16(suppl 14):31-37.
48. Rudy SJ, Parham-Vetter PC. Percutaneous absorption of topically applied medication. Dermatol Nurs 2003;15:145-146, 150-152.
49. Kara IO, Sahin B, Erkisi M. Palmar-plantar erythrodysesthesia due to do-cetaxel-capecitabine therapy is treated with vitamin E without dose reduction. Breast 2006;15:414-424.
50. Wilkes GM, Doyle D. Palmar-plantar erythrodysesthesia. Clin J Oncol Nurs 2005;9:103-106.
51. Lopez AM, Wallace L, Dorr RT et al. Topical DMSO treatment for pegy-lated liposomal doxorubicin-induced palmar-plantar erythrodysesthesia. Cancer Chemother Pharmacol 1999;44:303-306.